Esterase-Sensitive and pH-Controlled Carbon Monoxide Prodrugs for Treating Systemic Inflammation

A bottleneck
for developing CO-based therapeutics is the lack of
a safe and controllable delivery form. Herein, we describe efforts
toward organic CO prodrugs with dual-responsive endogenous triggers.
One representative CO prodrug showed significant anti-inflammatory
effects both in vitro and in a LPS-simulated systemic inflammation
model. These results firmly establish such CO prodrugs as either research
tools or candidate compounds for the treatment of systemic inflammation
or inflammation related organ injuries.